Through analyzing the activation of intratumoral pDCs, we found that shRNA treatment decreased the activation of pDCs (with decreased expression levels of CD80 and CD40 on pDCs in tumor sites), whereas therapy with both ssRNA and dual-function vector, compared with the control group, significantly enhanced the activation of intratumoral pDCs (Figure 5A). The gene discussed is CD80; the disease is neoplasm.